Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 0.4%.

  • China Pharma Holdings' Return on Capital Employed rose 1100.0% to 0.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4%, marking a year-over-year increase of 1100.0%. This contributed to the annual value of 0.43% for FY2024, which is 1600.0% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Return on Capital Employed is 0.4%, which was up 1100.0% from 0.42% recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Return on Capital Employed ranged from a high of 0.26% in Q1 2022 and a low of 0.83% during Q4 2022
  • For the 5-year period, China Pharma Holdings' Return on Capital Employed averaged around 0.43%, with its median value being 0.4% (2024).
  • As far as peak fluctuations go, China Pharma Holdings' Return on Capital Employed soared by 15700bps in 2021, and later crashed by -5500bps in 2022.
  • China Pharma Holdings' Return on Capital Employed (Quarter) stood at 0.29% in 2021, then tumbled by -189bps to 0.83% in 2022, then skyrocketed by 64bps to 0.3% in 2023, then plummeted by -65bps to 0.5% in 2024, then rose by 21bps to 0.4% in 2025.
  • Its Return on Capital Employed stands at 0.4% for Q3 2025, versus 0.42% for Q2 2025 and 0.47% for Q1 2025.